(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

Source: Getty Images ESMO 2024 featured studies that may change clinical practice for a range of cancers as well as studies that highlight the need for new approaches to cancer treatment.

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Source: Getty Images mRNA COVID-19 vaccines appear to increase PD-L1 expression across cancers, and this may explain the improved survival observed in vaccinated cancer patients receiving immune ...

Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.

Colorectal cancer Overall, patients who received ramucirumab did not have longer survival. However, women and patients with left-sided primary tumors did appear to derive a benefit from ramucirumab.

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

Source: Getty Images Phase 2 data support rovadicitinib as a new treatment option for patients with intermediate-2 or high-risk myelofibrosis who have not received prior JAK inhibitor treatment ...